From July 22 to 24, 2026,TONACEA will host the 1st China Pharmaceutical Innovation Conference(CPIC)at the National Exhibition and Convention Center (Shanghai).

Benchmarked against the J.P. Morgan Healthcare Conference, CPIC introduces a transformative model: "China Innovation – Global Partnerships – Shanghai Dealmaking."

As the prime gateway for overseas capital and enterprises to explore China’s innovation landscape, and a core hub for Chinese pharmaceutical companies to pursue global expansion and cross-border collaboration.

CPIC will serve as an annual bellwether for investment and partnership in the healthcare industry.

CPIC will feature dozens of specialized sessions covering hot topics and future directions in healthcare innovation investment and globalization.

Drug delivery systems and combination products represent the high-value frontier of the pharmaceutical innovation landscape. From regulatory frameworks and cutting-edge technologies to large-volume formulation trends and global expansion strategies, this session addresses the industry's most critical imperatives.

The complete agenda for the "International Advanced Drug Delivery Systems & Combination Products Session" is officially released today.

Organized by ESC MEDICAL and supported by Wanhai Medical and Aptar Pharma, this session will feature two high-level roundtable discussions focusing on the internationalization of combination products and the collaborative synergy between manufacturers and service providers.

By gathering collective industry intelligence, we aim to explore breakthrough strategies for industrial advancement.We look forward to exploring the future of drug-device integration with you at the National Exhibition and Convention Center (Shanghai) from July 22–24, 2026.

Scan the QR code to register now!
Limited-time early bird tickets at 40% off – grab yours now!!

About Fangda Partners

Special Session Schedule

Regulatory Administration of Combination Products in China

Senior Regulatory Expert

Frontiers of Combination Products
Zhen Gu: Assistant to the President, Zhejiang University; Director, State Key Laboratory of Advanced Drug Delivery Systems; Fellow, American Institute for Medical and Biological Engineering, International Academy for Medical and Biological Engineering, and Controlled Release Society

Development of Combination Products Amid the Boom of Large-Volume Subcutaneous Formulations
Liancheng Chen: CTO, ESC MEDICAL

Roundtable 1: Global Development of Combination Products

Lijie Zhang (Moderator): Founder, ESC MEDICAL 
Zheng Wang: Co-founder & CEO, Shanghai Bao Pharmaceuticals Co., Ltd.
Quanmin Chen: Vice President, Formulation Development & Clinical Manufacturing, WuXi Biologics
Additional speakers to be announced...

Roundtable 2: R&D Priorities for Manufacturers and Service Providers in Drug-Device Collaboration
Hua Huang (Moderator): CEO, ESC MEDICAL 
Yanhua Sun: Director, Peptide Drug Research Department, Qilu Pharmaceutical
Yingchun Li：Director, Biological Products Institute & Macromolecule CMC,R&D Institute, ‌CHIA TAI Tianqing Pharmaceutical Group Co., Ltd.
Additional speakers to be announced...

About ESC MEDICAL 

ESC MEDICAL (Suzhou) Co., Ltd. specializes in the R&D and supply of drug delivery devices, including auto-injectors, cartridge pens, and safety devices, along with comprehensive supply chain support. Our one-stop services encompass industrial design, engineering verification, design validation, prototyping, commercial manufacturing, testing and assembly solutions, as well as regulatory submission services.
Committed to advancing the biopharmaceutical industry through integrated delivery solutions, ESC MEDICAL empowers new drug development to achieve the vision of “Innovative Design, Shared Future.” Our tailored solutions meet diverse needs across R&D, clinical, registration, and commercialization stages. By providing full-cycle one-stop services, the company strives to become an industry-leading modern enterprise with standardized and sophisticated management.

About Wanhai Medical
 

Founded in 2016 and headquartered in Changzhou, Wanhai Medical is a National High-Tech Enterprise and a "Specialized, Refined, Differential and Innovative" Enterprise of Jiangsu Province, focusing on self-administration devices. With over a decade of expertise in the injector field, the company employs 300+ staff with an annual capacity of 120 million units. A new production base launched in 2025 covers approximately 2.3 hectares (34 mu) with a 40,000-sqm facility, boosting total annual capacity to over 400 million units upon completion.
Driven by automated intelligent manufacturing, Wanhai has established a vertically integrated industrial layout equipped with world-class precision equipment and intelligent cleanroom production lines. The company has secured CDE, NMPA, CE MDR, and ISO 13485 certifications, with FDA registration underway. With 70+ authorized patents and FTO (Freedom to Operate) clearance for all products, Wanhai recently secured a 100-million-yuan Series A investment from IDG Capital to accelerate its global expansion.

About Aptar Pharma
 

Aptar Pharma is a leading global drug delivery partner, providing innovative drug delivery systems, precision components, active packaging and digital health solutions for pharmaceutical, consumer healthcare and biotechnology clients worldwide.Its product portfolio covers multiple administration routes, including nasal, pulmonary, ophthalmic, transdermal and injectable delivery.
Supported by a comprehensive regulatory and laboratory service system, Aptar Pharma provides end-to-end support from early R&D to commercialization, helping clients accelerate development timelines and mitigate project risks. Continuously innovating to meet evolving needs of the healthcare market, customers, patients and end users, the company operates 18 GMP-compliant production sites globally, ensuring a stable, reliable supply chain and localized technical support.
Focused on technological breakthroughs, Aptar Pharma maintains a leading edge in next-generation drug delivery. It is a business segment of AptarGroup, Inc. (NYSE: ATR).